• Launched new Nasodine Throat Spray product in Singapore and Fiji
• Regulatory approval for Nasodine Nasal Spray in Philippines pending
• Positive shareholder and user survey results for Nasodine products

Firebrick Pharma Limited has released its Appendix 4D and half-year financial report for the period ended 31 December 2025. The key highlights include the launch of the company's new Nasodine Throat Spray product in Singapore and Fiji, as well as the pending regulatory approval for Nasodine Nasal Spray in the Philippines. The company also reported positive results from a shareholder sentiment survey and a Nasodine user survey, which showed high levels of satisfaction with the company's products and performance. Financially, the company reported a 12.66% decrease in net loss compared to the previous corresponding period, with a 17% reduction in overall operating expenses. The company continues to focus on international expansion and new product development, with plans to launch Nasodine Throat Spray in the US and explore opportunities in other Southeast Asian and Middle Eastern markets. While the report notes some material risks, such as manufacturing and execution risks and sales development challenges, the company remains optimistic about its future prospects.

Firebrick Pharma expects to see Nasodine approved and available in multiple countries in Southeast Asia and potentially elsewhere over the next several years. The company will remain a lean organization focused on international partnering, new intellectual property development, and new product development. Investors can expect to see new Nasodine products available in existing markets and regulatory approval and licensing in new markets, which will accelerate the company's progress towards profitability.